source
- Evaxion drops solid tumor vaccine program to prioritize brain cancer vaccine candidateEvaxion Biotech announced it has discontinued development of its next‑generation solid tumor vaccine, EVX‑03, and will redirect resources toward a brain cancer vaccine candidate developed with Duke…
- FDA clears Lantheus' Tauklarify PET imaging agent for Alzheimer’s tau detectionLantheus received FDA clearance for its PET imaging agent Tauklarify, also known as MK-6240, which is designed to help diagnose Alzheimer’s disease by visualizing tau protein deposits. The clearan…